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Abstract: Immune checkpoint inhibitors (ICIs) have shown significant efficacy in patients with various
malignancies, however, they are associated with a wide range of immune-related toxicities affecting many
organs, including the liver. Immune-mediated liver injury caused by checkpoint inhibitors (ILICI) is a
distinctive form of drug induced liver injury (DILI), that differs from most DILI types in presumed un-
derlying mechanism, incidence, and response to therapeutic interventions. Despite increased awareness
of ILICI and other immune-related adverse effects of ICIs reflected by recent guidelines for their man-
agement in post marketing clinical practice, there is lack of uniform best practices to address ILICI risk
during drug development. As efforts to develop safer and more effective ICIs for additional indications
grow, and as combination therapies including ICIs are increasingly investigated, there is a growing need
for consistent practices for ILICI in drug development. This publication summarizes current best prac-
tices to optimize the monitoring, diagnosis, assessment, and management of suspected ILICI in clinical
trials using ICI as a single agent and in combination with other ICIs or other oncological agents. It
is one of several publications developed by the IQ DILI Initiative in collaboration with DILI experts
from academia and regulatory agencies. Recommended best practices are outlined pertaining to hepatic
inclusion and exclusion criteria, monitoring of liver tests, ILICI detection, approach to a suspected ILICI
signal, causality assessment, hepatic discontinuation rules and additional medical treatment.
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Immune checkpoint inhibitors (ICIs) have shown significant efficacy in patients with various malignancies, 
however, they are associated with a wide range of immune-related toxicities affecting many organs, including 
the liver. Immune-mediated liver injury caused by checkpoint inhibitors (ILICI) is a distinctive form of drug 
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response to therapeutic interventions. Despite increased awareness of ILICI and other immune-related adverse 
effects of ICIs reflected by recent guidelines for their management in post marketing clinical practice, there is 
lack of uniform best practices to address ILICI risk during drug development. As efforts to develop safer and more 
effective ICIs for additional indications grow, and as combination therapies including ICIs are increasingly in-
vestigated, there is a growing need for consistent practices for ILICI in drug development. This publication 
summarizes current best practices to optimize the monitoring, diagnosis, assessment, and management of sus-
pected ILICI in clinical trials using ICI as a single agent and in combination with other ICIs or other oncological 
agents. It is one of several publications developed by the IQ DILI Initiative in collaboration with DILI experts 
from academia and regulatory agencies. Recommended best practices are outlined pertaining to hepatic inclu-
sion and exclusion criteria, monitoring of liver tests, ILICI detection, approach to a suspected ILICI signal, 
causality assessment, hepatic discontinuation rules and additional medical treatment.   
1. Introduction 
Experimental analysis of checkpoint signaling pathways involving 
primarily the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), 
programmed death-1 (PD-1) receptor and programed death ligand-1 
(PD-L1) has elucidated their important role in tumor-induced immune 
suppression and led to rapid progress in immunotherapeutic ap-
proaches to cancer treatment [1,2]. To date, 7 immune checkpoint in-
hibitors (ICIs) have been approved for clinical use, including the CTLA- 
4 inhibitor ipilimumab, the PD-1 inhibitors nivolumab, pem-
brolizumab, and cemiplimab and the PD-L1 inhibitors atezolizumab, 
avelumab, and durvalumab [2–4]. ICIs have led to significant increases 
in survival and/or response rates of patients with a variety of tumors, 
including advanced nonsquamous non-small-cell lung cancer (NSCLC), 
melanoma, renal cell carcinoma, squamous cell carcinoma of the head 
& neck, urothelial carcinoma, colorectal carcinoma, gastric carcinoma, 
hepatocellular carcinoma (HCC), Merkel cell carcinoma and Hodgkin's 
lymphoma [2,3,5]. However, these survival benefits come with a cost of 
immune-related adverse events (irAEs) affecting a variety of organs. 
These include, but are not limited to, infusion-related reactions, skin 
rashes, colitis, hepatic injury, pneumonitis, pericarditis, myocarditis, 
uveitis, and a number of different endocrinopathies [2,6–9]. 
Immune-mediated liver injury caused by ICIs (ILICI) (pronounced as 
“il-lis-e”) is a well-recognized irAE associated with ICIs and is a concern 
for patients, healthcare providers and the drug industry. ILICI is a un-
ique type of drug-induced liver injury (DILI), which generally differs 
from other types of DILI with respect to its suspected underlying me-
chanism, incidence, clinical manifestations and response to im-
munosuppression. As recently suggested by Hoofnagle and Björnsson 
[10], ILICI represents an example of a third type of DILI, which differs 
from idiosyncratic and direct hepatotoxicity, and is caused by an in-
direct effect of ICIs on the liver by virtue of their immune-mediated 
mechanism of action. ILICI may range in severity from mild, asymp-
tomatic elevations of serum aminotransferases (ATs) to acute liver 
failure [11–16]. Furthermore, combination therapies, of 2 ICIs or ICIs 
and other chemotherapies, which are commonly used in cancer pa-
tients, may have synergistic adverse effects which can significantly in-
crease the risk of liver injury [17,18]. 
Early detection and management of ILICI during drug development 
and post marketing are essential, given the potential adverse impact on 
clinical outcome. Despite increasing knowledge and understanding of 
irAEs caused by ICIs, there are no consistent practices regarding the 
monitoring, diagnosis, assessment, and management of ILICI during 
drug development. Although multiple societal, regulatory and in-
vestigator generated publications have proposed a variety of ap-
proaches to assessment and management of suspected ILICI, they have 
been inconsistent in several important areas, forcing drug developers to 
choose among conflicting recommendations when designing clinical 
trials using ICIs [2,6–9,19–21]. 
The IQ DILI Initiative was launched in June 2016 within the 
International Consortium for Innovation and Quality in Pharmaceutical 
Development (also known as the IQ consortium) to attain consensus 
and to propose best practices on topics related to clinical DILI [22]. The 
IQ Consortium is a science-focused, not-for-profit organization addres-
sing scientific and technical aspects of drug development. It is com-
prised of over 40 pharmaceutical and biotechnology companies. The 
IQ-DILI Initiative is an affiliate of the IQ Consortium, comprised of 
representatives from 18 IQ member companies. The purpose of IQ DILI 
is to establish evidence-based best practices for diagnosing, monitoring, 
managing, and preventing DILI. 
This publication is based on an extensive literature review, a survey 
of current approaches used by IQ DILI members, and consensus 
achieved through structured discussions among IQ DILI members and 
academic and regulatory experts, which together comprised the IQ DILI 
Immunotherapy Working Group (IQ DILI IWG). This publication fo-
cuses on liver injury caused by ICIs, which constitute the most com-
monly used agents for cancer immunotherapy to date. Other categories 
of cancer immunotherapy, such as cytokine treatment, drugs that en-
hance cytokine production, costimulatory receptor agonists, oncolytic 
viruses, anti-tumor vaccines, and adoptive cell transfer are not dis-
cussed. Of note, most of the data, and recommendations that are in-
cluded in this publication are specific for acute hepatocellular ILICI. 
However, ILICI may present as mixed or cholestatic liver injury in a 
significant minority of affected patients [23–26]. Because of scarcity of 
data in the published literature to inform best practices regarding the 
evaluation and management of the cholestatic type of ICI associated 
liver injury, cholestatic ILICI, is only briefly discussed. Nevertheless, 
drug developers and investigators must remain mindful of this less 
common type of liver injury during ICI development and post mar-
keting use. 
2. Terminology 
2.1. Commonly used terms 
The terminology used to describe hepatic events related to ICIs, has 
been largely inconsistent. Terms used in published literature include: 
“immune-related (or mediated) liver injury”, “immune-related (or 
mediated) hepatotoxicity”, “Immune-related (or mediated) hepatitis”, 
“hepatic immune-related adverse events”, “ICI-induced liver injury”, 
“ICI-associated immune-mediated hepatitis”, “checkpoint-induced liver 
injury”, “autoimmune-like hepatitis”, “immune-induced hepatitis”, 
“dysimmune hepatitis”, “transaminitis” and others 
[2,7,9,16,18–20,27–34]. Some of these terms imply various underlying 
mechanisms or specific histological findings, while others remain in-
completely defined. The interchangeable use of these may be confusing 
and difficult to follow. Because of these limitations, it is the consensus 
of the IQ DILI IWG that “immune-mediated liver injury caused by 
checkpoint inhibitors” (ILICI) is a preferred and appropriate term to 
describe this type of injury. 
2.2. Serum aminotransferase elevation in ILICI 
In some publications, any elevations of serum alanine 
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aminotransferase (ALT) or aspartate aminotransferase (AST) above the 
upper limit of normal (ULN), were used to define ILICI. This conflicts 
with current approaches to other types of hepatocellular DILI [35,36]. 
Indeed, most authorities in DILI agree that mild asymptomatic increases 
in serum ALT or AST (> 1x to < 3x ULN) in the absence of an elevation 
in serum total bilirubin level (TBL) are often not specific and may be 
related to causes such as nonalcoholic fatty liver disease (NAFLD), 
changes in diet, and vigorous exercise [35–37]. Patients with malig-
nancy often have alternative causes of ALT and AST elevations such as 
primary liver tumors, hepatic metastasis, intra- or extra-hepatic biliary 
obstruction, systemic infection, sepsis, systemic immune-related syn-
drome, congestive heart failure and concomitant medications [38]. 
Furthermore, mild elevations in ALT or AST, even if drug induced, may 
be transient and spontaneously revert to baseline even when therapy is 
continued, an occurrence often referred to as “adaptation” [35,36,39]. 
Consistent with this phenomenon, most cases with transient mild 
asymptomatic elevation of ALT > 1x ULN to < 3x ULN induced by ICIs, 
without elevation of serum TBL, do not represent clinically significant 
cases of ILICI, and are more accurately referred to as “elevations in 
serum ATs”. 
2.3. Use of histological terminology in the absence of a liver biopsy 
Since information regarding histological findings in patients with 
ILICI is still limited, broad use of histology-based terminology is not 
recommended pending a larger body of evidence. For example, the use 
of the term “hepatitis” in patients with ILICI (e.g., “ICI-associated he-
patitis” or “immune-mediated hepatitis”) is appropriate only when di-
agnosed based on histological examination. This is in keeping with the 
Council for International Organizations of Medical Sciences (CIOMS) 
guidelines [40]. In the absence of a liver histology, the term ILICI is 
preferred. 
In ILICI cases with a biochemical pattern consistent with cholestatic 
liver injury, i.e., predominantly elevated serum alkaline phosphatase 
(ALP) and gamma-glutamyl transferase (GGT) with R ratio < 2, the IQ 
DILI IWG recommends “cholestatic ILICI” as the preferred term. Terms 
like “ICI-related cholangitis”, “ICI-induced cholangitic liver disease” or 
“biliary pattern hepatitis”, which have been used variably in the lit-
erature, should be reserved for cases with histological findings or other 
reliable diagnostic tests (e.g., cholangiography) that are supportive of 
these terms [23–25]. 
2.4. Liver dysfunction and liver failure 
Terms such as “liver dysfunction” and “liver failure”, have been 
used to describe cases of ILICI in the published literature. However, 
these cases often do not exhibit true abnormal synthetic liver function, 
but instead are based on isolated elevation of serum ATs. Clinical and 
regulatory guidelines recommend these terms be reserved for cases with 
evidence of decreased liver function based on elevated serum levels of 
direct bilirubin (DBL), prolonged prothrombin time (PT) or interna-
tional normalized ratio (INR) (INR > 1.5), hepatic encephalopathy, or 
ascites caused by impaired hepatic function [35]. 
2.5. Common terminology criteria for adverse events (CTCAE) 
In most published oncology studies, including those using ICIs, liver 
test abnormalities are graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) versions 3 
to 5, which categorize serum ALT and AST elevations as grade 1 
(> ULN-3x ULN), grade 2 (> 3–5x ULN), grade 3 (> 5–20x ULN), and 
grade 4 (> 20x ULN) [41]. Because of the prevalent use of the CTCAE 
grading system, only a minority of clinical trials using ICIs provide 
detailed data on subgroups of ALT or AST elevations such as > 8x ULN 
or > 10x ULN. The CTCAE assigns each grade a severity degree: grade 
1, mild; grade 2, moderate; grade 3, severe, and grade 4, life 
threatening. However, there are few published data to support an as-
sociation between the magnitude of ALT or AST elevation and the 
clinical outcome of the liver injury [42,43]. As a result, most authorities 
avoid the use of the severity terminology for the various CTCAE stages 
[42,44]. For practical purposes, the IQ DILI IWG agreed to use the 
CTCAE grading scale (grades 1 through 5) in this consensus paper, to 
align with data provided in many published clinical studies of ICIs. 
2.6. Consensus and recommendations  
1. The preferred term for cases of liver injury caused by ICIs is “im-
mune-mediated liver injury caused by immune checkpoint in-
hibitors” (ILICI).  
2. For patients with mild asymptomatic elevations of serum ALT or 
AST (< 3x ULN) the terms “ALT elevation” or “AST elevation” are 
preferred to “ILICI”.  
3. Until a larger histological database of patients with suspected ILICI 
is available, the term “hepatitis” should be reserved for patients who 
have histological findings consistent with hepatitis.  
4. In established ILICI with predominantly elevated serum ALP and 
GGT, the preferred term is “cholestatic ILICI”. Histologic terms such 
as “cholangitis” should be reserved for patients who have supportive 
histological findings or results of other reliable diagnostic tests.  
5. In patients with ILICI, the terms “liver dysfunction” and “liver 
failure” should be reserved for those with evidence of decreased 
liver function (e.g., prolonged PT/INR or elevated serum levels of 
DBL or TBL) or evidence of acute decompensation (e.g., hepatic 
encephalopathy, ascites).  
6. It is recommended to avoid the use of clinical severity terms (e.g., 
mild, moderate, severe, as suggested by CTCAE grading) based so-
lely on elevated ALT or AST levels in patients with ILICI. 
3. ILICI incidence in clinical trials 
The reported incidence of ILICI varies among the different agents as 
well as across trials and indications. Furthermore, reported rates differ 
considerably due to differences in terminology and variations in ALT or 
AST cutoff values used to define ILICI. In most large clinical trials using 
a single ICI, serum ALT elevations  >  ULN occurred in 3–15% of pa-
tients during ICI treatment [16,45–54]. A few studies reported a higher 
incidence; however, these data are difficult to interpret because a 
substantial percentage of mild ALT changes (< 3x ULN) were transient 
or not related to exposure to the study drug [18,55,56]. Grade 3 ALT 
elevations (ALT > 5–20x ULN) occurred in 0–3% of the patients treated 
with a single ICI, while grade 4 ALT elevations (ALT > 20x ULN) oc-
curred in 0–0.5% of the cases [46,49,51–53,57–62]. These incidence 
rates are consistent with retrospective studies from the US and France 
which showed grade 3–4 ILICI incidence of 1.7% and 3% in 5762 and 
536 patients, respectively [33,34]. The incidence of ILICI associated 
with ipilimumab monotherapy, ranging between 3 and 9%, was on 
average higher than that of other ICIs [2,52,53,55,63,64]. 
While well documented in the post-marketing setting, concomitant 
elevation of serum ALT > 3x ULN and total bilirubin (TBL) > 2x or   
> 3x ULN has been infrequent in clinical trials using ICIs 
[12,13,33,65]. Acute liver failure due to ICIs was also rarely reported in 
clinical trials, and mostly observed post-marketing [12,13,15,33]. A 
recent meta-analysis reported 8 fatal ILICI cases out of 19,127 treated 
patients (0.042%) [66]. In a few studies the incidence of ILICI appeared 
to be dose dependent [3,67–69]. 
To date, published data are insufficient to estimate the true in-
cidence of cholestatic ILICI, defined as an R value (serum ALT/ULN 
divided by serum ALP/ULN)  <  2, measured near the time of onset of 
liver injury [37]. Acute cholestatic ILICI has been reported infrequently 
in clinical trials, however, in post marketing reports cholestatic or 
mixed liver injury was reported in up to 20–30% of affected patients 
[23–26]. In retrospective post marketing studies, patients with 
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cholestatic injury were uncommon, or were not included in the analysis 
[26,33,34]. In one retrospective analysis, of 20 patients who were ad-
judicated as definite or highly likely to be drug-related, 40% had an 
acute hepatocellular pattern (R value  > 5), 25% had a mixed pattern 
(R value 2–5), and 35% had a cholestatic pattern at the onset of liver 
injury [26]. However, since ALP elevations are often the result of 
tumor-related causes, it is difficult to determine the true incidence of 
cholestatic and mixed ILICI. 
3.1. Combination anti-neoplastic regimens in clinical trials 
Accumulated evidence suggests that combinations of two or more 
ICIs or of one ICI with other chemotherapeutics with hepatotoxic po-
tential may increase the incidence of ILICI [6,8,17,33,54,70,71]. An-
imal studies have shown that concomitant checkpoint inhibition in-
creases the risk of DILI due to drugs with a known DILI risk, such as 
amodiaquine [72]. In clinical trials combinations of two ICIs (e.g., 
ipilimumab and nivolumab) were associated with higher incidence of 
serum ALT elevations (11–18% grade ≥3) compared to individual 
administration as monotherapy (0–3%) [17,54,73]. An increased in-
cidence of ALT elevations was also observed using a combination of 
vemurafenib (BRAF inhibitor) and ipilimumab. In a phase I study, 4 of 6 
patients had grade 3 ALT or AST elevations in one cohort, and 3 of 4 
patients had grade 2 or 3 ALT or AST elevations in a second cohort, 
which led to an early termination of the study [68]. It should be noted 
that the liver adverse events were asymptomatic and were reversible 
upon discontinuation of the study drug and the administration of cor-
ticosteroids in a few instances. In a prospective clinical trial comparing 
ipilimumab plus dacarbazine to dacarbazine plus placebo in patients 
with metastatic melanoma, grade 3–4 ALT elevations occurred in 20.7% 
of the patients using the ipilimumab-dacarbazine combination com-
pared to 0.8% of patients on dacarbazine alone. Grade 4 ALT elevations 
occurred in 5.2% of the patients on ipilimumab-dacarbazine versus 0% 
of the patients on dacarbazine only [70]. Furthermore, the rate of grade 
3–4 ALT elevation was higher with the combination of ipilimumab- 
dacarbazine compared to that reported for ipilimumab alone (20.7% vs. 
8% respectively) [70,74,75]. The reason for the apparent increase in 
the rate of liver injury associated with combination ipilimumab-da-
carbazine remains unclear. It has been postulated that the increase in 
liver injury rates may be related to lowering of the immune threshold to 
dacarbazine-related DILI, induced by ipilimumab. 
A higher incidence of ILICI with the combination of two ICIs has 
also been reported in the clinical practice setting [33,34]. In a recent 
retrospective study of 5762 patients, combination therapy of two ICIs 
was found to be associated with an ILICI rate (grade 3–4 ALT elevation) 
of 9.2% compared to 1.7% with monotherapy [33]. 
Despite a paucity of clinical evidence, it is believed, that patients 
who have received previous ICI treatment are at an increased risk of 
DILI from a subsequent drug with hepatotoxic potential (whether an ICI 
or not), compared to patients who were not previously exposed to ICIs. 
There are a few case reports to support this notion, but it largely re-
mains untested [71]. 
3.2. Special populations 
Pre-existing chronic liver disease. Hepatic safety data in patients 
with chronic liver disease such as chronic hepatitis B or C, alcohol- 
related liver disease or nonalcoholic steatohepatitis (NASH) remain 
scarce, because most initial studies using ICIs excluded such patients 
[76]. However, reports of ICI treatment in patients with chronic he-
patitis B or C are increasing, mainly due to the use of ICIs for the 
treatment of hepatocellular carcinoma (HCC) [32,77–79]. Based on 
recent studies, both nivolumab and pembrolizumab have gained ac-
celerated approval status from FDA for the treatment of HCC 
[62,79–81]. A few authors have suggested that ICIs may promote 
worsening of underlying liver disease through various speculative 
mechanisms; however, evidence for this remains insufficient [2,18,77]. 
In chimpanzees with naturally occurring hepatitis B virus (HBV), dosing 
with pembrolizumab was associated with serum AT elevations in 2 out 
of 4 animals. These AT elevations were not completely resolved at the 
end of a 4-week off-dosing period [62,82]. The underlying mechanism 
of this finding is unclear. In a woodchuck model of chronic hepatitis 
virus (which closely resembles human chronic HBV infection), the ad-
dition of anti-PD-L1 antibody to an anti-viral regimen significantly 
enhanced the suppression of hepatitis virus, leading to complete viral 
clearance in some cases [83]. Similarly, when 3 chimpanzees with 
persistent hepatitis C virus (HCV) infection were treated with multiple 
doses of anti-PD-1 antibody, there was a significant reduction in viral 
load in one animal in the absence of apparent hepatic injury [84]. In 
cirrhotic patients with HCV infection who were treated for HCC with 
tremelimumab, the frequency of grade 3–4 ALT elevation (25%) was 
notably higher than in HCC patients without HCV (3%) [60,85]. 
However, some ALT elevations were likely caused by the underlying 
HCV rather than by tremelimumab. Interestingly, tremelimumab 
treatment was associated with a progressive decrease in HCV viral load 
(HCV RNA) in most patients followed for at least 3 months [85]. In 
other reports of smaller sample size, ILICI was either not observed or 
was uncommon (grade 3 ALT elevation in one case) in patients with 
either HBV or HCV, including those with detectable viral load treated 
with ipilimumab, pembrolizumab, nivolumab or atezolizumab. In ad-
dition, none of the patients had significant changes in HCV viral load 
[77,78]. Other case reports have shown no effect on HCV RNA during 
ICIs treatment with or without concomitant direct acting antiviral 
therapy for HCV [86]. Recently, the American Society of Clinical On-
cology (ASCO) and the Friends of Cancer Research advocated that 
clinical trial eligibility criteria for ICIs be expanded, to reflect ‘real- 
world’ treatment populations (including chronic hepatitis B or C), 
which may aid in better characterization of the safety of ICIs in patient 
populations with pre-existing chronic liver disease [2,87,88]. 
Liver transplant recipients. Hepatic safety of ICIs in liver trans-
plant recipients is controversial, because of conflicting reports re-
garding the risk of ILICI and graft rejection in this patient population 
[78,89,90]. The increasing number of published reports of allograft 
rejection has raised questions about publication bias [32]. However, 
reports of severe rejection resulting in death emphasize the need for a 
cautious approach to treatment and close monitoring in liver transplant 
recipients treated with ICIs [78,91]. 
3.3. Consensus   
7. The incidence of ILICI varies among different ICIs and clinical 
trials. Most publications reported the incidence of grade 3 serum 
ALT elevations (> 5–20x ULN) to be 1–2.5% of the patients treated 
with a single ICI. Grade 4 ALT elevations (> 20x ULN) occurred in 
0–0.5% of cases. Generally, the frequency of ALT elevations was 
higher with the CTLA-4 inhibitor, ipilimumab, than with PD-1 and 
PD-L1 inhibitors.  
8. Grade 3–4 serum TBL elevation (> 3x ULN) with concurrent ALT 
elevation was reported in less than 0.1% in patients treated with a 
single ICI.  
9. Liver failure attributed to ICIs has been reported rarely.  
10. Generally, combination therapy with two or more ICIs or an ICI 
with another chemotherapeutic drug with a known DILI risk, has 
been associated with a higher rate of grade 3–4 ALT elevations. The 
incidence of grade 3–4 ALT elevations varies among specific drug 
combinations. 
11. Data from animal studies suggest that concurrent checkpoint in-
hibition may increase the risk of DILI caused by other drugs with a 
known risk of DILI.  
12. Limited data exist regarding the risk of ILICI in patients with 
chronic liver disease including chronic hepatitis B or C, alcoholic 
liver disease or NASH. 
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13. Cases of cholestatic ILICI have been reported; however, the in-
cidence of this type of liver injury is not clearly defined. 
14. The incidence of ILICI or graft rejection in liver transplant re-
cipients is not yet established, but an increased risk seems likely, 
based upon published reports. 
4. Hepatic inclusion and exclusion criteria in ICI clinical trials 
In general, the purpose of hepatic inclusion and exclusion criteria is 
to minimize potential DILI risk, prevent drug accumulation due to di-
minished hepatic excretion/metabolism, and decrease confusion be-
tween potential DILI and progression of preexisting liver disease. 
Hepatic inclusion and exclusion criteria have varied considerably 
among ICI trials (Suppl Table S1). Exclusion criteria for serum ATs have 
ranged between > 1.5x ULN and > 3x ULN in patients without hepatic 
metastases [45,56,61,70,92–94]. In patients with hepatic metastases 
most studies have allowed inclusion of patients with serum ALT or AST 
levels of up to 5x ULN [50,56,94–96]. Exclusion criteria for serum TBL 
typically have ranged from > 1.0x ULN to > 2.5x ULN, with the ex-
ception of patients with Gilbert's syndrome who were enrolled with 
higher serum TBL, usually < 3.0 mg/dL [45,50,56,61,92,94–100]. Of 
note, the diagnosis of Gilbert's syndrome in a patient with elevated TBL, 
is typically confirmed by calculating the amount of DBL, which should 
be less than 30% of the TBL, in the absence of hemolysis [101,102]. In a 
few ICI studies, DBL  >  ULN has been added as a separate exclusion 
criterion [50]. To date, most ICI clinical trials in patients with HCC 
have excluded patients with baseline serum ALT or AST > 5x ULN, or 
TBL > 2.5x ULN [85]. No consistent differences exist between the ex-
clusion criteria used in particular studies, the types of cancer, or the 
specific ICIs being administered. Moreover, no systematic trials have 
been performed to compare and assess different thresholds of serum 
ALT, AST, and TBL for enrollment criteria. Thus, no data exist to favor 
one set of criteria over another. 
Most studies of ICIs for patients with cirrhosis and HCC have ex-
cluded patients with advanced liver disease defined by a Child Turcotte 
Pugh (CTP) score of > 7 (CTP class C or class B with a score of 8–9) 
[79–81]. Very few studies allowed inclusion of CTP class B with a score 
of 8–9, however CTP class C (score 10–15) were generally excluded 
[85]. This reduces the likelihood of confusing ILICI (or other types of 
DILI) for development of a complication of cirrhosis such as hepatic 
decompensation or portal vein thrombosis, which are more likely in 
patients with advanced liver disease. 
While initial clinical trials of ICIs excluded patients with chronic 
liver disease due to hepatitis B or C (Suppl Table S1), a growing body of 
evidence indicates that such patients may not exhibit a significantly 
increased risk of ILICI or reactivation of hepatitis B or C 
[77–79,85,103,104]. Indeed, the increased use of ICIs for treatment of 
HCC in patients with chronic HBV or HCV infection (major risk factors 
for the development of HCC) have shown promising results 
[79,81,104]. In most such studies, patients with HBV infection were 
required to be on suppressive nucleos(t)ide analogue therapy with a 
viral load (HBV DNA)  < 100 IU/mL during screening. Direct acting 
antiviral therapy to achieve a sustained virologic response was not a 
prerequisite for ICI treatment of patients with HCV infection [79,85]. 
Interestingly, antiviral T-cell activities regulated by the PD-1/PD-L1 
pathway are known to be decreased in chronic viral hepatitis (HBV, 
HCV), and in vitro studies suggest that blocking this pathway may re-
duce viremia [105,106]. This is in accordance with evidence of a de-
creased HCV viral load (HCV RNA) observed in HCC patients treated 
with the CTLA-4 inhibitor tremelimumab [85]. 
The question of whether patients with preexisting autoimmune 
hepatitis (AIH) can be enrolled in clinical trials using ICIs, is still un-
resolved. Although prospective data are scarce, some evidence suggests 
that patients with a history of autoimmune disorders, such as rheu-
matoid arthritis, systemic lupus erythematosus, autoimmune thyr-
oiditis, psoriasis, and inflammatory bowel disease, are at a higher risk 
of irAEs and flares of their preexisting autoimmune disorders while on 
ICIs [107–109]. However, these events were often mild, manageable, 
and did not typically necessitate discontinuation of ICI therapy, while a 
significant proportion of patients achieved clinical anti-cancer re-
sponses. Nevertheless, such events may be severe on occasion [109]. At 
present, there are no published data documenting flares of idiopathic 
AIH. Extrapolation from the data on other autoimmune diseases sug-
gests that in some instances ICIs can be administered relatively safely to 
patients with idiopathic AIH with close monitoring of hepatic bio-
chemical tests [107–109]. A liver biopsy prior to initiation of treatment 
may help in the assessment of disease activity and severity [110]. 
4.1. Consensus and recommendations   
15. To allow accurate evaluation of ILICI risk as well as DILI risk due to 
concomitant medications, it is recommended that patients with 
serum ALT > 3x ULN be excluded from ICI clinical trials unless 
HCC metastatic disease is present. In the presence of hepatic pri-
mary or metastatic disease it is recommended to exclude patients 
with serum ALT > 5x ULN.  
16. Since elevated serum ALP is common in patients with malignancy, 
using serum ALP levels as an exclusion criterion in otherwise eli-
gible study participants is generally not recommended.  
17. It is recommended that patients with a baseline elevation of 
TBL > 1.5x ULN be excluded. Patients with a TBL elevation due to 
Gilbert's syndrome can be included in clinical trials using ICIs, 
provided that the serum DBL is less than 30% of the TBL, in the 
absence of hemolysis.  
18. Patients with chronic hepatitis B can be enrolled in clinical trials of 
ICIs, if they have baseline serum HBV DNA < 100 IU/mL and 
normal or near normal serum ALT (< 1.5x ULN), while on treat-
ment with anti-HBV therapy using an approved nucleos(t)ide ana-
logue.  
19. Patients with acute hepatitis A, B, C, D or E, reactivated hepatitis B, 
or active delta hepatitis should be excluded until their clinical 
status and liver disease stabilize.  
20. Patients with a history of chronic hepatitis C or positive anti HCV 
antibody who have undetectable serum HCV RNA at baseline 
(following anti-HCV treatment or after spontaneous clearance) may 
be enrolled in clinical trials of ICIs with routine monitoring of ALT, 
AST and TBL according to the protocol schedule.  
21. Patients with chronic hepatitis C and detectable serum HCV RNA 
may be enrolled in clinical trials with ICIs. There are no consistent 
recommendations regarding anti-HCV treatment in these patients. 
It is recommended to obtain serum HCV RNA whenever serum ALT 
increases to > 3x ULN.  
22. There are limited data regarding the safety and efficacy of ICI 
therapy in patients with idiopathic AIH. Despite the absence of 
published reports, a flare of idiopathic AIH remains a theoretical 
risk of ICI therapy.  
23. Patients with idiopathic AIH may be enrolled in clinical trials with 
ICIs if their disease is stable, well-controlled with im-
munosuppressive therapy, and with normal or near normal liver 
tests. A liver biopsy prior to initiation of ICI treatment can help in 
assessing the activity and severity of the AIH.  
24. Patients with idiopathic AIH, whose liver disease is well controlled 
with immunosuppressive therapy should continue receiving their 
therapy during ICI treatment. Investigators should be mindful of 
the potential risk of a flare of idiopathic AIH and should follow 
these patients closely.  
25. There are insufficient published data to recommend inclusion or 
exclusion of liver transplant recipients in clinical trials with ICIs. 
5. Hepatic monitoring and ILICI detection 
Close monitoring of clinical status and liver test results is critically 
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important for early detection, risk assessment, and management of ILICI 
during drug development for ICIs [2,7,8,21,35]. Since ILICI most 
commonly presents with asymptomatic elevations of serum ATs, most 
cases have been detected through monitoring of hepatic biochemical 
tests. Serum ALP typically remains within the normal range in ILICI, but 
mild elevations, usually < 2x ULN, may occur. In a minority of the 
patients, ILICI presented with hepatic symptoms such as general 
weakness, fatigue, abdominal discomfort, nausea, vomiting, or fever 
[15]. Generally, patients with symptomatic ILICI tended to have higher 
serum ATs, which may be  >  20x ULN and occasionally > 40x ULN 
[23]. The typical time to onset (latency) ranged from 2 to 24 weeks 
(median 4–16 weeks) from initiation of ICI treatment, although several 
well documented ILICI cases occurred after longer treatment duration 
(e.g., 48 weeks) (Suppl Table S2) [7,11,33,63,81,111–114]. 
Most clinical trials of ICIs require serial assessments for signs and 
symptoms of liver injury, and hepatic biochemical tests (serum ALT, 
AST, ALP, and TBL) every 2–3 weeks during the first 2–3 months, and 
every 3–4 weeks thereafter [46,60,100,115]. Typically, assessments are 
made before the subsequent cycle of ICI treatment, ending 1–3 months 
after completion or discontinuation of treatment. This is in keeping 
with general recommendations made in the US FDA's guidance on the 
premarketing evaluation of DILI [35] as well as clinical practice 
guidelines from ASCO, the European Society for Medical Oncology 
(ESMO), Society for Immunotherapy of Cancer (SITC), and the National 
Comprehensive Cancer Network (NCCN) [7–9,21]. 
In general, when assessing a case of suspected DILI in patients 
without underlying liver abnormalities, the magnitude of change in 
hepatic biochemical tests is determined in comparison to the ULN [35]. 
In patients with preexisting elevations of liver tests it has been re-
commended to assess the change in comparison to the patient's baseline 
values [35,41,116]. Therefore, it is crucial to establish a baseline for 
reference, prior to ICI initiation. Since serum ALT levels in some on-
cology patients can fluctuate even over short periods of time (especially 
in the presence of hepatic tumors or metastases and with certain 
Table 1 
Recommended management of treatment emergent abnormal hepatic biochemical tests in clinical trials with ICIs (patients with normal or near-normal baseline ALT, 
ASTa [ < 1.5x ULN]).       
CTCAE grade of ALT/ 
AST elevation 
Serum ALT or AST Serum TBLb ICI treatment adjustment and additional 
therapy 
Monitoring and evaluation  
Grade 1 ALT or AST  >  ULN 
–3x ULN 
Normal   
Patients with Gilbert's synd: 
No change in baseline TBL 
Continue treatment Repeat blood testsc within 1–2 weeks. 
Grade2 ALT or AST  > 3–5x 
ULN 
Normal   
Patients with Gilbert's synd: 
No change in baseline TBL 
WithholdICI treatment. 
If rising ALT/AST when re-checked, start 
oral prednisone/prednisolone 1 mg/kg/df 
Repeat blood testsd within 2–5 days. Initiate 
close monitoringe and evaluation (Table 3). 
Grade 2 ALT or AST  > 3–5x 
ULN 
TBL ≥2x ULN   
Patients with Gilbert's synd: 
Doubling of direct bilirubin 
Discontinue ICI treatment. 
Start I.V. (methyl) prednisolone 1–2 mg/ 
kg/df 
Repeat blood testsd within 2–3 days. Initiate 
close monitoringe and evaluation (Table 3). 
Grade 3 ALT or AST  > 5–10x 
ULN 
Normal   
Patients with Gilbert's synd: 
No change in baseline TBL 
Withhold ICI treatment. 
Start oral prednisone/prednisolone 1–2 mg/ 
kg/df 
Repeat blood testsd within 2–3 days. Initiate 
close monitoringe and evaluation (Table 3). 
Grade 3 ALT or AST  > 5–10x 
ULN 
TBL ≥2x ULN   
Patients with Gilbert's synd: 
Doubling of direct bilirubin 
Discontinue ICI treatment. 
Start oral prednisone/prednisolone 1–2 mg/ 
kg/df 
Repeat blood testsd within 2–3 days. Initiate 
close monitoringe and evaluation (Table 3). 
Grade 3 ALT or AST  > 10–20x 
ULN 
Normal or abnormal Discontinue ICI treatment. 
Start I.V. (methyl)prednisolone 1–2 mg/kg/ 
dg 
Repeat blood testsd within 2–3 days. Initiate 
close monitoringe and evaluation (Table 3). 
Grade 4 ALT or AST  > 20x ULN Normal or abnormal Discontinue ICI treatment. 
Start I.V. (methyl) prednisolone 2 mg/kg/dg 
Repeat blood testsd within 2–3 days. Initiate 
close monitoringe and evaluation (Table 3). 
Abbreviation used: ALP, alkaline phosphatase, ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; DBL, direct bilirubin; GGT, 
gamma glutamyl transferase; ICI, immune checkpoint inhibitors; INR, International Normalized Ratio; MMF, mycophenolate mofetil; TBL, total bilirubin; ULN, upper 
limit of normal. 
a Use of serum ALT is preferred over AST due to its higher hepatic specificity. ALP is not included in this table as isolated ALP elevation is often related to the 
underlying malignancy and uncommonly related to ILICI. Furthermore, there are limited published data regarding management of ILICI in patients who develop 
isolated ALP elevation during ICI treatment. 
b Measurement of total and conjugated (or direct) bilirubin is recommended to help identify patients with indirect hyperbilirubinemia due to Gilbert's syndrome or 
hemolysis versus liver injury. 
c Recommended blood tests include ALT, AST, ALP, GGT, TBL. 
d Recommended blood tests include: ALT, AST, ALP, GGT, TBL, DBL, CK, INR. 
e Initial monitoring should be 2–3 times a week. Frequency of monitoring may be adjusted based on clinical scenario and severity of injury. Monitoring should 
continue until levels return to Grade 1, regardless of whether or not the ICI had been discontinued. 
f Oral prednisone/prednisolone: if hepatic biochemical tests worsen on oral prednisone/prednisolone, change to I.V. (methyl)prednisolone. Once hepatic 
biochemical tests return to Grade 1, corticosteroids can be weaned over 2–4 weeks. ICI treatment may be resumed with close monitoring, once prednisone/ 
prednisolofe dose ≤10 mg/day. 
g I.V. (methyl)prednisolone: if worsening continues on I.V. (methyl)prednisolone, consider adding MMF 500–1000 mg twice daily. See additional options in text. 
Once hepatic biochemical tests return to Grade 1, corticosteroids can be weaned over 4 weeks. ICI treatment may be resumed with close monitoring, once pre-
dnisone/prednisolone dose ≤10 mg/day.  
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concomitant anti-neoplastic agents), a single measurement on a given 
day may not be representative of a patient's true baseline. Thus, it has 
been suggested to obtain at least two serum ALT measurements at least 
one week apart prior to treatment initiation and to use the average of 
the two values as the baseline value [37,116]. These two measurements 
can be performed at the “screening visit” (typically visit 1) and the 
“baseline visit” just prior to initiation of the study drug (typically visit 2 
or 3). Most clinical trials of ICIs require at least 2 baseline measure-
ments of serum ALT, AST, ALP and TBL to provide reference values for 
assessing any on treatment changes. If the two ALT values differ 
by > 50%, and the higher value is  > 2x ULN, it has been re-
commended to consider performing a third test to determine the di-
rection of the change, and to consider evaluation for cause prior to 
enrollment [116,117]. 
In keeping with the FDA's guidance on DILI and clinical guidelines 
on ILICI, it has been strongly recommended to initiate close observation 
immediately upon detection and confirmation of early signs of possible 
ILICI, and not to wait until the next scheduled visit or monitoring in-
terval. Serum ALT levels greater than 3x ULN (in patients with normal 
or near normal baseline ALT) or greater than 2x baseline value (in 
patients with baseline ALT ≥1.5x ULN) have been proposed for 
initiation of close observation [7–9,21,35]. Close observation usually 
includes repeat testing of ALT, AST, TBL, DBL, ALP and GGT, followed 
by serial monitoring of these tests (initially, 2–3 times a week) (Tables 1 
and 2). Once an abnormality is confirmed, a comprehensive assessment 
should be undertaken to determine the likelihood of ILICI and exclude 
alternative causes of liver injury [7–9,21,35,37,116,117]. Initial mon-
itoring should be done at a frequency of 2–3 times weekly, based on the 
clinical condition and hepatic biochemical tests. Subsequently, the 
frequency of monitoring may be reduced to once every 1–2 weeks, if the 
clinical condition and lab results stabilize [7–9,21,35]. 
5.1. Consensus and recommendations   
26. ILICI most commonly presents as asymptomatic serum ALT and 
AST elevation with ALP levels in the normal or moderately elevated 
range, a pattern consistent with hepatocellular or mixed injury.  
27. Reference-baseline values of serum ALT may need to be established 
based on a calculation of the average of two consecutive ALT levels 
performed at least 1 week apart prior to initial dosing (preferably 
during the screening and baseline visits). If the two ALT values 
differ by > 50%, and the higher value is  > 2x ULN, it is 
Table 2 
Recommended management of treatment emergent abnormal hepatic biochemical tests in clinical trials with ICIs (patients with abnormal baselineALT, ASTa [≥1.5x 
ULN]).      
Serum ALT or AST Serum TBLb ICI treatment adjustment and additional therapy Monitoring and evaluation  
ALT or AST  >  BLV –2x BLV Normal   
Patients with Gilbert's synd: No 
change in baseline TBL 
Continue treatment Repeat blood testsc within 1–2 weeks. 
ALT or AST  > 2–3x BLV Normal   
Patients with Gilbert's synd: No 
change in baseline TBL 
Withhold ICI treatment. 
If rising ALT/AST when re-checked, start oral 
prednisone/prednisolone 1 mg/kgf 
Repeat blood testsd within 2–5 days. Initiate close 
monitoringe and evaluation (Table 3). 
ALT or AST  > 2–3x BLV TBL ≥2x ULN   
Patients with Gilbert's synd: 
Doubling of direct bilirubin 
Discontinue ICI treatment. 
Start I.V. (methyl) prednisolone 1–2 mg/kgf 
Repeat blood testsd within 2–3 days. Initiate close 
monitoringe and evaluation (Table 3). 
ALT or AST  > 3–  < 5x BLV Normal   
Patients with Gilbert's synd: No 
change in baseline TBL 
Withhold ICI treatment. 
Start oral prednisone/prednisolone 1–2 mg/kgf 
Repeat blood testsd within 2–3 days. Initiate close 
monitoringe and evaluation (Table 3). 
ALT or AST  > 3–  < 5x BLV TBL ≥2x ULN   
Patients with Gilbert's synd: 
Doubling of direct bilirubin 
Discontinue ICI treatment. 
Start oral prednisone/prednisolone 1–2 mg/kgf 
Repeat blood testsd within 2–3 days. Initiate close 
monitoringe and evaluation (Table 3). 
ALT or AST  > 5x BLV Normal or abnormal Discontinue ICI treatment. 
Start I.V. (methyl) prednisolone 1–2 mg/kgg 
Repeat blood testsd within 2–3 days. Initiate close 
monitoringe and evaluation (Table 3). 
ALP, alkaline phosphatase, ALT, alanine aminotransferase; AST, aspartate aminotransferase; BLV, baseline value; Dir Bil, direct bilirubin; ICI, immune checkpoint 
inhibitors; INR, International Normalized Ratio; MMF, mycophenolate mofetil; TBL, total bilirubin; ULN, upper limit of normal. 
a Use of serum ALT is preferred over AST due to its higher hepatic specificity. ALP is not included in this table as isolated ALP elevation is often related to the 
underlying malignancy and less commonly related to ILICI. Furthermore, there are limited published data regarding management of ILICI in patients who develop 
isolated ALP elevation during ICI treatment. 
b Measurement of total and conjugated (or direct) bilirubin is recommended to help identify patients with indirect hyperbilirubinemia due to Gilbert's syndrome or 
hemolysis versus liver injury. 
c Recommended blood tests include ALT, AST, ALP, GGT, TBL. 
d Recommended blood tests include: ALT, AST, ALP, GGT, TBL, Dir Bil, CK, INR. 
e Initial monitoring should be 2–3 times a week. Frequency of monitoring may be adjusted based on clinical scenario and severity of injury. Monitoring should 
continue until levels return to Grade 1, regardless of whether or not the ICI had been discontinued. 
f Oral prednisone/prednisolone: if hepatic biochemical tests worsen on oral prednisone/prednisolone, change to I.V. (methyl)prednisolone. Once hepatic 
biochemical tests return to Grade 1, corticosterids can be weaned over 2–4 weeks. ICI treatment may be resumd with close monitoring, once prednisone/prednisolone 
dose ≤10 mg/day. 
g I.V. (methyl)prednisolone: if worsening continues on I.V. (methyl)prednisolone, consider adding MMF 500–1000 mg twice daily. See additional options in text. 
Once hepatic biochemical tests return to Grade 1, corticosteroids can be weaned over 4 weeks. ICI treatment may be resumed with close monitoring, once pre-
dnisone/prednisolone dose ≤10 mg/day.  
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recommended to perform a third test to determine the direction of 
the change, and to consider evaluation for the cause.  
28. In patients with a normal or near normal baseline serum ALT 
(< 1.5x ULN), a confirmed ALT elevation of ≥3x ULN, regardless 
of hepatic symptoms or TBL values, is a reasonable threshold to 
initiate close observation and more frequent monitoring (Table 1)  
29. In patients with an elevated baseline serum ALT (≥1.5xULN), an 
ALT elevation of > 2x baseline, even in the absence of hepatic 
symptoms or elevated TBL, is a reasonable threshold to initiate 
close observation and monitoring (Table 2).  
30. In patients meeting the criteria for possible ILICI, an assessment for 
hepatic signs or symptoms and liver tests (including ALT, AST, ALP, 
TBL) should be repeated within 2–3 days and at least weekly 
thereafter until a return to pre-event baseline values occurs. The 
specific interval between the tests should be determined based on 
the patient's clinical condition and the course of change in hepatic 
biochemical tests. 
6. Special considerations for causality assessment of suspected 
ILICI 
Like other DILI types, causality assessment in patients with sus-
pected ILICI is challenging and largely dependent on the exclusion of 
other possible causes of liver injury [118]. A comprehensive discussion 
of principles and methods of causality assessment is beyond the scope of 
this publication. The following section addresses specific considerations 
pertinent to ILICI. 
Abnormal liver tests related to ILICI should be differentiated from 
those that may occur due to other causes of liver injury associated with 
the underlying malignancy or concomitant medications. Patients with 
malignant tumors may have elevated serum levels of ALT, AST or ALP, 
due to a variety of causes including hepatic metastases, biliary ob-
struction, hepatic vein thrombosis, congestive heart failure, systemic 
infections, metastatic spread to bone and other organs [26,38,119]. 
They may also develop DILI due to drugs other than ICIs, as well as from 
herbal/dietary supplements. The frequency of serum ALP > 1x ULN 
ranges between 37.2% in patients without detectable hepatic metas-
tases and as high as 67% in patients with hepatic metastases [119]. The 
pattern of liver injury in ILICI is typically hepatocellular, or (less often) 
Table 3 
Recommended evaluation of patients with treatment-emergent grade 2–4 ALTelevation during a clinical trial with ICIsa.    
Recommended evaluation Competing causes of abnormal liver tests 
1st Line Testing  
Thorough history of symptoms, co-existing medical conditions, concomitant medications, 
dietary and nutritional supplements, excessive exercise or muscle injury, alcohol 
consumption, illicit substances. 
Systemic infection/sepsis; ischemic/congestive hepatic injury; gallstone disease; 
alcoholic liver disease; muscle injury/rhabdomyolysis; acetaminophen toxicity; DILI 
due to another drug, herbal or dietary supplement. 
Serum CK Muscle injury/rhabdomyolysisc 
Anti-HAV (IgM) Acute HAV infection 
HBsAg 
Anti-HBc IgG, IgM, HBV DNA 
Acute hepatitis B; Exacerbation of chronic hepatitis B 
Anti-HCV 
HCV RNA (PCR) 
Acute hepatitis C; 
Exacerbation of chronic hepatitis Cb 
Anti-HEV (IgG, IgM); HEV RNAd Acute hepatitis E 
ANA, ASMA 
Quantitative immunoglobulins (IgG, IgM, IgA) 
Autoimmune hepatitise 
Hepatobiliary imaging (ultrasonography, CT scan, MRI, MRCP)f Biliary obstruction; pancreatitis; gallstones; portal-vein/hepatic vein thrombosis; 
hepatic metastasis 
2nd Line Testing 
Serological tests for EBV, CMV, HSV. 
May need to obtain acute and convalescent serological tests; 
Hepatic injury caused by CMV, EBV, HSV 
EBV-DNA, CMV-DNA, HSV-DNA by PCR. liver biopsy needed to confirm HSV Hepatic injury caused by CMV, EBV, HSV 
Additional Testsg 
Anti-LKM-1 Autoimmune hepatitis 
Serum EtOH 
Urinary ethyl-glucuronide and ethyl-sulfateh, Serum phosphatidylethanoli 
Alcohol related liver disease 
Serum acetaminophen level; Acetaminophen protein adducts Acetaminophen toxicity 
Review of blood pressure, pulse, electrocardiogram, echocardiogram, cardiology consult Ischemic or congestive hepatic injury 
Urine toxicology screen Hepatotoxicity due to cocaine, amphetamines, opiates and other illicit substances 
Anti-HDV Hepatitis D 
Blood or urine cultures Systemic infection, sepsis 
Blood ceruloplasmin, serum copper 
Slit lamp eye examination for Kayser-Fleischer rings, genetic testing 
Wilson's disease 
Abbreviations used: CMV, Cytomegalovirus; CK, creatine kinase; DILI, drug induced liver injury; EBV, Epstein Bar Virus; HBV, hepatitis B virus, HBsAg, hepatitis B 
surface antigen; HCV, hepatitis C virus; HDV, hepatitis D virus; HEV, hepatitis E virus; HSV; Herpes Simplex Virus; LKM-1, liver kidney microsomal type 1. 
a Extent and type of work-up may vary by patient's history, severity of liver injury, underlying disease, and geography. 
b Acute hepatitis C may be anti-HCV negative but HCV RNA positive. 
c Serum AST typically (although not always) is higher than ALT. 
d If anti-HEV IgM positive, consider confirmation with HEV RNA by nested PCR. 
e A liver biopsy is needed to confirm a diagnosis of AIH. 
f If cholestatic injury, MRCP may be recommended. 
g Based on medical history and clinical judgment. 
h Alcohol consumption in past 3–5 days. 
i Alcohol consumption in past 3 weeks.  
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mixed, i.e., predominantly ALT and AST elevation, with a R value  > 5 
or 2–5, and therefore usually easy to differentiate from hepatic me-
tastasis, which is typically cholestatic. Nevertheless, ILICI may infre-
quently also present as cholestatic injury (R value  < 2), which can 
cause a diagnostic dilemma [23,24,26]. 
A comprehensive causality assessment is required in all patients 
who meet criteria for suspected ILICI during a clinical trial (Table 3). A 
recent retrospective study found that fewer than 30% of patients who 
met criteria for liver injury (serum ALT ≥5x ULN/baseline, ALP ≥2x 
ULN/baseline, TBL ≥2.5 mg/dL or 2x baseline) had ILICI based on 
adjudication by expert opinion [26]. Most clinical trials have required 
the following assessment for patients with suspected ILICI: (1) a thor-
ough history of symptoms, concomitant medications (including recent 
acetaminophen overdose), use of herbal/dietary and nutritional sup-
plements, and recent alcohol consumption; (2) repeat testing of ALT, 
AST, ALP, TBL, DBL, and albumin, followed by close monitoring of 
these biochemical tests; (3) testing of serum for viral hepatitis including 
hepatitis A, B, C, E, and testing for HDV in patients who are infected 
with HBV; (4) serological tests for autoimmune hepatitis, including 
anti-nuclear antibodies (ANA), anti-smooth muscle antibodies (ASMA), 
anti-kidney microsomal antibodies, and quantitative immunoglobulins; 
(5) hepatobiliary imaging to rule out other causes of liver injury such as 
cholecystitis, choledocholithiasis, biliary obstruction, and hepatic vein 
thrombosis. If results of the initial testing do not reveal an alternative 
cause, additional tests may be considered, including tests for cytome-
galovirus (CMV), Epstein Barr virus (EBV), herpes simplex virus (HSV), 
additional imaging, and/or a liver biopsy. A consultation with a clin-
ician knowledgeable in DILI or a hepatologist has been recommended to 
assess complex cases. This approach is consistent with most published 
clinical guidelines pertaining to post marketing assessment of patients 
with suspected ILICI [7–9,21]. To enable an analysis of hepatotoxic 
risk, it is important to systematically collect and document the results of 
these tests in the patient's case report forms [35]. 
In patients receiving a combination of an ICI and a non-ICI drug that 
may have a hepatotoxic liability, differentiating between ILICI and DILI 
due to the concomitant non-ICI drug can be especially challenging. 
Moreover, as described above, certain combined treatments have 
shown more liver toxicity than each component alone. Concurrent 
irAEs (e.g., skin manifestations, colitis, thyroiditis, pneumonitis), which 
are relatively common in patients with ILICI, occurring in about 
30–47%, may indicate that the ICI is a more likely cause of liver injury 
than the non-ICI drug, but other factors (e.g., temporal relationship, 
dechallenge, rechallenge, known DILI phenotype of each drug) must be 
considered [15,18,33,34,71]. 
In some cases, it may be difficult to differentiate between ILICI and 
idiopathic AIH. One important distinguishing feature is that in contrast 
to a high recurrence rate of classical idiopathic AIH after discontinua-
tion of corticosteroid treatment, in ILICI, corticosteroid treatment ty-
pically leads to a long-lasting resolution of liver test abnormalities after 
ICI discontinuation [18,33]. Recurrence of ILICI after steroid with-
drawal has been reported in only 14% of patients [33]. Furthermore, in 
contrast to idiopathic AIH, in which 90% of patients have high titers of 
serum autoantibodies, including ANA, anti-double stranded DNA anti-
body, and ASMA, most ILICI cases are marked by the absence of ele-
vated titers of these antibodies [2,33,34,120,121]. Liver histology may 
also be helpful in differentiating between ILICI and idiopathic AIH (see 
below). 
Imaging studies do not show specific findings associated with ILICI 
and may show either normal appearance or mild periportal lympha-
denopathy, periportal edema or hepatomegaly in severe cases. 
However, imaging studies may be helpful in ruling out other causes of 
acute increase in liver tests, such as worsening of hepatic metastasis, 
biliary obstruction, and hepatic vein or portal vein thrombosis [13,23]. 
According to most experts, liver biopsy is usually not necessary for 
the routine diagnosis or management of ILICI but may be helpful in 
patients who fail to respond to conventional therapy, or in whom the 
diagnosis is questionable due to atypical presentation or unusual clin-
ical course [7–9,21,122]. In such cases, liver histology can provide 
important and useful information on the pattern of injury and its se-
verity and may help identify causes other than ILICI 
[23,25,31,34,122–124]. In most patients with ILICI, liver histo-
pathology does not show a highly specific or diagnostic picture. It ty-
pically shows a predominantly mononuclear inflammation that may 
range between mild portal infiltrate with or without interface hepatitis 
and diffuse panlobular inflammation with prominent perivenular in-
filtrate or confluent necrosis. Scattered plasma cells and occasional 
eosinophils may also occur [23,31,122,123]. However, the lack of 
plasma cell predominance in the lymphocytic infiltrate, which is a 
classic hallmark of AIH, may help differentiate between ILICI and 
idiopathic AIH [122]. In one study which compared ILICI to idiopathic 
AIH, ILICI was associated with less zone-selective necrosis and fewer 
CD20+ B cells and CD4+ T cells compared to AIH [31]. The less 
common cholestatic injury of ILICI may show a mononuclear infiltrate 
in portal tracts that is centered around bile ducts and bile ductular 
proliferation, consistent with primary injury to bile ducts or acute 
cholangitis [23,25]. A recent single center study reported distinct his-
topathological patterns for anti-CTLA4 and anti-PD-1/PD-L1 agents, 
with anti-CTLA4 drugs inducing a specific pattern of granulomatous 
hepatitis associated with severe lobular necrotic and inflammatory ac-
tivity, fibrin deposits and central vein endothelialitis and a more het-
erogeneous histological pattern in the case of hepatotoxicity related to 
anti-PD-1/PD-L1 agents [34]. 
ILICI usually resolves within 4–6 weeks with interruption/dis-
continuation of the ICI and appropriate immunosuppressive treatment 
(see below) [7,21,33]. Most guidelines agree that if the serum ALT level 
fails to decrease substantially within 4–6 weeks of treatment for ILICI, 
alternative diagnoses must be reconsidered, and a diagnostic assess-
ment should be repeated including, if possible, a liver biopsy [7,21]. 
6.1. Consensus and recommendations   
31. In patients with or without hepatic metastases and normal or near 
normal baseline serum ALT (< 1.5x ULN), an increase of ALT to 
≥3x ULN should prompt an evaluation for possible causes in-
cluding possible ILICI versus tumor progression (Table 3). 
32. In patients with or without hepatic metastases and elevated base-
line serum ALT (≥1.5x ULN), an increase of ALT to ≥2x baseline 
should prompt an evaluation for possible causes including possible 
ILICI versus tumor progression (Table 3). 
33. In patients with a normal baseline serum ALP, an increase of pre-
dominantly ALP to ≥2x ULN should trigger an evaluation for 
possible causes including cholestatic ILICI, tumor progression, 
biliary obstruction, systemic infection, bone disease, or DILI due to 
a concomitant medication.  
34. In patients with an elevated baseline ALP, an increase of ALP to 
≥2x baseline, should prompt an evaluation for possible causes 
including cholestatic ILICI, tumor progression, biliary obstruction, 
systemic infection, bone disease, or DILI due to a concomitant 
medication.  
35. In patients with a treatment emergent serum ALP elevation without 
a significant elevation in serum ALT, other causes (e.g., worsening 
of hepatic or bone metastases, biliary obstruction) are more likely 
to be the cause than ILICI.  
36. If serum AST increases with a less pronounced increase in serum 
ALT, alternative causes other than ILICI, should be sought, in-
cluding muscle injury and alcohol related liver disease. 
37. Failure to respond to discontinuation of ICIs and initiation of cor-
ticosteroid therapy within 4–6 weeks should warrant a repeat 
evaluation for other possible causes of liver injury and considera-
tion of a liver biopsy. 
38. ILICI patients typically do not have elevated titers of serum auto-
antibodies (e.g., ANA and ASMA) or increased serum IgG levels. 
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High titers of serum autoantibodies are more indicative of idio-
pathic AIH and should warrant further evaluation (including a 
possible liver biopsy) and appropriate follow-up for idiopathic AIH.  
39. Liver biopsy typically is not required for the diagnosis of ILICI, but 
it can be helpful in patients who fail to respond to conventional 
therapy, or for those in whom the diagnosis is doubtful due to an 
atypical presentation or clinical course.  
40. Liver biopsy may be helpful in distinguishing between ILICI and 
idiopathic AIH.  
41. In a patient receiving combination treatment, a liver biopsy may be 
helpful in distinguishing between ILICI and DILI caused by a non- 
ICI drug.  
42. It is recommended to save serum samples for testing for rare causes 
of liver injury. The collection of genomic DNA from patients with 
liver injury is encouraged in order to perform relevant testing for 
potential genetic susceptibility markers at a later date. 
7. ILICI management: ICIs interruption and pharmacological 
treatment 
7.1. General considerations 
In contrast to most other DILI types, the recommended management 
of ILICI involves not only interruption/discontinuation of the suspected 
culprit drug, but often initiation of immunosuppressive therapy with 
corticosteroids such as methyl prednisolone or its equivalent (Tables 1 
and 2) [7–9,21,33]. It is important to note that current management 
recommendations have been derived largely from practices employed 
in registration trials and are not derived from randomized controlled 
datasets. In most cases, management recommendations are based on 
changes in serum ALT, AST and TBL rather than ALP, since an isolated 
ALP elevation is often related to the underlying malignancy and less 
commonly due to ILICI [7,8,21]. Moreover, there are limited published 
data regarding management of ILICI in patients who develop isolated 
serum ALP elevation during ICI treatment. Generally, the use of serum 
ALT is preferred over AST due to its higher hepatic specificity. Typi-
cally, ILICI resolves within 4–6 weeks of interrupting ICI treatment and 
initiating corticosteroids, although occasionally, abnormal hepatic 
biochemical test persist or worsen despite these measures. In cases of 
ILICI worsening, second line therapy in clinical trial protocols and in 
clinical practice has consisted of a course of mycophenolate mofetil 
(MMF) in addition to corticosteroids [7,8,21,33]. In rare case reports, 
use of third line immunosuppressive therapy has been employed, in-
cluding anti-thymocyte globulin (ATG), calcineurin inhibitors, ritux-
imab, and others [125–127]. In general, there is insufficient prospective 
evidence to support one immunosuppressive therapeutic approach over 
another. Consequently, most drug developers and professional societies 
have based their practices on empiric considerations, and expert-con-
sensus, often in alignment with prior ICI clinical trial protocols. In a few 
reports, patients with grade 3 ILICI experienced spontaneous resolution 
after withholding ICI treatment without initiation of corticosteroid 
therapy [34,128]. 
The following is a summary of the practices adopted in many ICI 
clinical trial protocols, which are endorsed by most of the clinical 
guidelines. Based on the IQ DILI IWG consensus, serum ALT is used as 
the predominant biomarker in management recommendations, since it 
is considered more specific for liver injury and more strongly associated 
with hepatocellular DILI than is serum AST. 
7.2. Management of study participants with normal or near normal baseline 
serum ALT (< 1.5x ULN) (Table 1) 
Grade 1 ALT elevation (ALT  >  ULN-3x ULN): Most clinical trial 
protocols and guidelines call for closer monitoring (e.g., weekly or bi-
weekly) for signs and symptoms of liver injury and hepatic biochemical 
tests, including serum ALT, AST, ALP, TBL, and DBL [7,8,21,129]. A 
detailed medical history should be obtained, including concomitant 
medications, over the counter products, alcohol or other substance 
abuse, as well as herbal and dietary supplements. Most guidelines do 
not call for treatment interruption with grade 1 changes [7,8,21,129]. 
Frequency of monitoring can be adjusted based on extent and trajectory 
of ALT elevation. 
Grade 2 serum ALT elevation (ALT > 3-5x ULN): Most clinical 
trials and guidelines recommend withholding ICI treatment and in-
itiating close monitoring for signs and symptoms of liver injury and 
hepatic biochemical tests, including serum ALT, AST, ALP, TBL, and 
DBL twice weekly. Suppl Table S3 outlines examples of treatment in-
terruption and discontinuation criteria used in ICIs clinical trials. If ALT 
returns to baseline values within 1–2 weeks, ICI treatment can be re-
sumed with close monitoring of hepatic biochemical tests. Persistent 
grade 2 elevation lasting longer than 1–2 weeks, calls for evaluation for 
alternative causes of liver injury (Table 3), and initiation of oral cor-
ticosteroid therapy (prednisolone, methylprednisolone or equivalent) at 
a dose of 0.5–1 mg/kg/day. If the abnormality improves to grade 1, the 
dose of corticosteroids can be tapered over 4–6 weeks. Upon im-
provement, ICI therapy may be resumed once the dose of corticosteroid 
reaches 10 mg/day. If no improvement occurs after initiation of corti-
costeroids, the corticosteroid dose should be increased to 2 mg/kg/day 
(prednisolone, methylprednisolone, or equivalent) and the route of 
administration may be switched to intravenous (IV) methylpredniso-
lone. In addition, permanent discontinuation of ICI therapy should be 
considered [7–9,21,62]. 
Grade 3 or 4 serum ALT elevation (> 5x ULN): Most clinical trials 
and guidelines recommend withholding of ICI therapy and initiating 
corticosteroid therapy (prednisolone, methylprednisolone or equiva-
lent) at 1–2 mg/kg/day [7–9,21,62,129]. Oral prednisolone/methyl-
prednisolone at a dose of 1 mg/kg/day is recommended for grade 3 
elevation, while 2 mg/kg/day of IV methylprednisolone is re-
commended for grade 4 elevations. If there is no response to corticos-
teroids within 2–3 days, most guidelines recommend the addition of 
mycophenolate mofetil 500–1000 mg twice daily, consultation with a 
hepatologist, and consideration of a liver biopsy [7–9,14,21,129]. 
There are insufficient data to support a specific third-line im-
munosuppressive therapy. Successful use of anti-thymocyte globulin 
(ATG) has been reported in a few cases [130–132]. Other agents that 
have been used empirically, include calcineurin inhibitors (tacrolimus 
or cyclosporine), rituximab (anti-CD20 monoclonal antibody), and to-
cilizumab (anti-interleukin-6 receptor monoclonal antibody) 
[125,133]. Despite limited evidence, most experts do not recommend 
the use of infliximab (anti-tumor necrosis factor alpha monoclonal 
antibody) given the concern of hepatotoxicity [7,9,21]. A few groups 
have suggested a more selective use of corticosteroids in some patients 
with grade 3 ILICI, especially when liver histology shows less severe 
injury; however, more data are needed before this approach can be 
widely adopted [18,34]. 
While a thorough evaluation for alternative causes of liver injury 
should be initiated as soon as possible, there is strong agreement among 
drug developers and published guidelines that immunosuppressive 
therapy, if needed, should be initiated without delay in the absence of 
any other apparent cause [7,8,21]. 
In general, most guidelines strongly agree that ICI therapy be per-
manently discontinued whenever the serum ALT elevation is  >  10x 
ULN, or if the ALT elevation is accompanied by increase in TBL > 2x 
ULN (see rechallenge below) [7–9,21]. 
Elevated TBL: Generally, most guidelines agree that patients with 
grade 2 serum ALT elevation, who have a concomitant TBL elevation 
≥2x ULN should be managed as grade 3–4 ALT elevation, unless the 
bilirubin elevation is caused by Gilbert's syndrome [7–9,21]. 
A. Regev, et al.   Journal of Autoimmunity 114 (2020) 102514
10
7.3. Management of study participants with elevated baseline serum ALT 
(≥1.5x ULN) (Table 2) 
Patients with metastatic cancer or primary hepatic tumors fre-
quently have abnormal hepatic biochemical tests at the time of en-
rollment. In such cases the thresholds for hepatic monitoring, treatment 
discontinuation and initiation of immunosuppression therapy may be 
difficult to implement. Under these circumstances, it has been sug-
gested to use multiples of baseline serum ALT rather than multiples of 
ULN as a threshold for suspecting DILI [35,36,116,117]. 
In the absence of large prospective comparative data, there is little 
evidence to support specific thresholds for initiation of close mon-
itoring, withholding of ICI treatment and initiation of im-
munosuppressive therapy, although several approaches have been 
proposed for patients with pre-existing liver diseases [35,36,116,117].  
Table 2 outlines an approach suggested by the IQ DILI IWG for patients 
with elevated baseline serum ALT≥ 1.5x ULN. 
7.4. Drug rechallenge 
While a general discussion of drug rechallenge in patients with DILI 
or ILICI is beyond the scope of this publication, it is important to note 
that close monitoring is critically important in these circumstances, as 
liver injury may recur rapidly and may be difficult to control. 
Most ICI clinical trials and guidelines have allowed restarting 
treatment (also known as rechallenge) in patients with grade 2 serum 
ALT elevation which returned to baseline after treatment-interruption, 
with or without corticosteroid treatment. While most clinical trials have 
avoided resuming treatment in patients with grade 3 or 4 ALT elevation 
who returned to baseline, more recent clinical trials and guidelines 
have allowed restarting treatment if a grade 3 ALT elevation did not 
exceed 10x ULN and was not accompanied by elevated TBL of > 2x 
ULN [7,8,21,62]. In a retrospective study from MD Anderson Cancer 
Center, 31 patients restarted ICI therapy after ILICI had improved 
to ≤ grade 1 ALT (< 3x ULN). Twenty-nine of these patients had grade 
3, and 2 had grade 4 ILICI. Restarting of ICI therapy led to recurrent 
ILICI in 8 (26%) of the cases [33]. All the 8 cases initially had grade 3 
ILICI, and in all 8, ICIs were stopped permanently after recurrent ILICI 
[33]. In another retrospective study, resumption of ICIs (specifically of 
anti–PD-1 therapy) led to recurrent ILICI in 17% of the cases [134]. 
These reports highlight the need to refine the management of specific 
ILICI cases, however additional prospective data are necessary. 
In special circumstances, when ICI treatment is critical to the pa-
tient's anti-cancer regimen, it has been recommended that the pros/ 
benefits and cons/risk of restarting the treatment be discussed with the 
patient and/or his or her health-care proxy and that written informed 
consent be obtained prior to restarting of ICI therapy [33,135]. 
7.5. Consensus and recommendations   
43. Restarting ICI therapy may be considered in patients with ILICI who 
had grade 2 serum ALT elevation and normal TBL that returned to 
baseline values.  
44. Restarting of ICI therapy may be considered in patients with ILICI 
who had grade 3 serum ALT elevation without a significant ele-
vation in TBL (unless diagnosed with Gilbert's syndrome), provided 
ALT did not exceed 10x ULN and returned to baseline value.  
45. A liver biopsy may be helpful in deciding on whether ICI therapy 
can be resumed after resolution of ILICI. Less severe histologic 
disease has been cited as a reason to restart therapy after resolution 
of ILICI.  
46. There are limited data on the efficacy of prophylactic corticosteroid 
therapy administered prior to resumption of ICI therapy for pre-
vention of recurrent ILICI.  
47. In patients who resume ICI treatment after resolution of ILICI it is 
recommended to monitor liver tests at least weekly for the first 2 
months and every 2 weeks for the 3rd month. Monitoring frequency 
may change based on the severity of preceding ILICI.  
48. In special circumstances, it is recommended that written informed 
consent detailing the benefit and risk of restarting the treatment, be 
obtained prior to resuming ICI therapy. 
8. Summary 
The number of clinical trials using ICIs as single agents or in com-
bination with other anti-tumor treatments is increasing rapidly and 
there is a growing need for clear and consistent practices pertaining to 
detection, assessment, and management of ILICI during drug develop-
ment. Early detection and management of ILICI are paramount and may 
have a critical impact on the success of immunotherapy. This publica-
tion provides a framework for recommendations based on the colla-
borative work of the IQ DILI initiative with experts from academia and 
other experts in the DILI field. Future analysis of cross industry clinical 
trial data may provide crucial information to further understand ILICI 
and improve our approach to its assessment and management. 
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